Nothing Special   »   [go: up one dir, main page]

AU2003251650A1 - Screening for agents suitable for treatment of leukocyte associated inflammatory diseases - Google Patents

Screening for agents suitable for treatment of leukocyte associated inflammatory diseases

Info

Publication number
AU2003251650A1
AU2003251650A1 AU2003251650A AU2003251650A AU2003251650A1 AU 2003251650 A1 AU2003251650 A1 AU 2003251650A1 AU 2003251650 A AU2003251650 A AU 2003251650A AU 2003251650 A AU2003251650 A AU 2003251650A AU 2003251650 A1 AU2003251650 A1 AU 2003251650A1
Authority
AU
Australia
Prior art keywords
screening
treatment
inflammatory diseases
agents suitable
associated inflammatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003251650A
Other versions
AU2003251650A8 (en
Inventor
Martin Gosling
Sau Wei Li
Christopher Terence Poll
John Westwick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0217503.2A external-priority patent/GB0217503D0/en
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2003251650A8 publication Critical patent/AU2003251650A8/en
Publication of AU2003251650A1 publication Critical patent/AU2003251650A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/04Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2003251650A 2002-07-29 2003-07-28 Screening for agents suitable for treatment of leukocyte associated inflammatory diseases Abandoned AU2003251650A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0217503.2 2002-07-29
GBGB0217503.2A GB0217503D0 (en) 2002-07-29 2002-07-29 Organic compounds
US41512402P 2002-09-30 2002-09-30
US60/415,124 2002-09-30
PCT/EP2003/008313 WO2004013629A2 (en) 2002-07-29 2003-07-28 Screening for agents suitable for treatment of leukocyte associated inflammatory diseases

Publications (2)

Publication Number Publication Date
AU2003251650A8 AU2003251650A8 (en) 2004-02-23
AU2003251650A1 true AU2003251650A1 (en) 2004-02-23

Family

ID=31497250

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003251650A Abandoned AU2003251650A1 (en) 2002-07-29 2003-07-28 Screening for agents suitable for treatment of leukocyte associated inflammatory diseases

Country Status (4)

Country Link
EP (1) EP1527343A2 (en)
JP (1) JP2005534311A (en)
AU (1) AU2003251650A1 (en)
WO (1) WO2004013629A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080221025A1 (en) * 2005-01-12 2008-09-11 Sanofi-Aventis Deutschland Gmbh Use of Trpc Channel for the Treatment of a Cardiovascular Disease
EP2052724A1 (en) * 2007-10-26 2009-04-29 sanofi-aventis Use of norgestimate as a selective inhibitor of TRPC3, TRPC6 and TRPC6 and TRPC7 ion channel
KR100953821B1 (en) * 2007-12-03 2010-04-21 순천향대학교 산학협력단 Biomarker for diagnosing asthma and therapeutic agent of asthma controlling expression of vitamin D binding protein
EP2368876A1 (en) * 2010-03-01 2011-09-28 Sanofi Derivatives of aminoindanes, their preparation and their application in therapeutics
CN103966309B (en) * 2013-02-04 2016-01-27 中国科学院上海生命科学研究院 Peripheral blood cells TRPC6mRNA level is used for early prediction/diagnosis senile dementia

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1099296C (en) * 1996-01-11 2003-01-22 韦尔斯利医院基金会 Compositions including calcium influx retardant for inhibiting cell growth
AU5229199A (en) * 1998-07-24 2000-02-14 South Alabama Medical Science Foundation Use of decreasing levels of functional transient receptor potential gene product
US20030079243A1 (en) * 2000-12-11 2003-04-24 Allen Keith D. Transgenic mice containing TRP6 calcium ion channel gene disruptions

Also Published As

Publication number Publication date
EP1527343A2 (en) 2005-05-04
AU2003251650A8 (en) 2004-02-23
WO2004013629A2 (en) 2004-02-12
JP2005534311A (en) 2005-11-17
WO2004013629A3 (en) 2004-05-06

Similar Documents

Publication Publication Date Title
AU2003301347A1 (en) Methods for monitoring treatment of disease
AU2003285091A1 (en) Interferon antagonists useful for the treatment of interferon related diseases
HK1082256A1 (en) New compounds, compositions and methods for treatment of inflammatory diseases and conditions
WO2003072035A8 (en) Compositions and methods for the treatment of immune related diseases
WO2004041170A9 (en) Compositions and methods for the treatment of immune related diseases
EP1592384A3 (en) Cop 1 for treatment of inflammatory bowel diseases
WO2004024097A9 (en) Compositions and methods for the treatment of immune related diseases
AU2003228819A1 (en) Combinations for the treatment of inflammatory skin disorders
GB0329874D0 (en) Compounds useful for the treatment of diseases
EP1611120A4 (en) Novel methods for the treatment of inflammatory diseases
AU2003298911A1 (en) Cyclosporins for the treatment of autoimmune diseases
PL371281A1 (en) Methods and compositions for the treatment of eye diseases
AU2003212245A1 (en) Method of diagnosis of inflammatory diseases using calgranulin c
AU2002309180A1 (en) Composition and kit for the treatment of inflammatory bowel diseases
AU2003259833A1 (en) Methods of treating neurodegenerative diseases
WO2004024076A8 (en) Novel compositions and methods for the treatment of immune related diseases
AU2003251650A1 (en) Screening for agents suitable for treatment of leukocyte associated inflammatory diseases
AU2003237150A1 (en) Compositions and methods for treating inflammatory connective tissue diseases
AU2003272962A1 (en) Remedies for allergic diseases
AU2003232844A1 (en) Morpholin-acetamide derivatives for the treatment of inflammatory diseases
AU2003900639A0 (en) Novel method of treating inflammatory diseases
AU2003297912A1 (en) Methods for screening compounds for use in the treatment of disease
AU2003295504A1 (en) Development of therapeutics for the treatment of endotoxin-mediated diseases
AU2003208809A1 (en) Treatment of neuroblastoma
AU2003242246A1 (en) Remedy for bone mtabolic diseases